A complete joint treatment

I-ONE® therapy

ICEA®
CLINICAL BIOPHYSICS

I-ONE® therapy

A complete joint treatment

I-ONE® THERAPY DELIVERS A SIGNAL PERMEATING THE ENTIRE EXTENSION AND DEPTH OF THE ARTICULAR CARTILAGE AS WELL AS THE ARTICULAR STRUCTURES AND THE SUBCHONDRAL BONE.



Cartilage

I-ONE® therapy stimulates the synthesis of the cartilage matrix and exercises a chondroprotective effect.

Synovia

I-ONE® therapy exerts an anti-inflammatory effect, decreasing the release of catabolic factors (TNF-α, IL-6, IL-8, IL-1β, PGE2) and increasing the production of anabolic factors (IL-10, TGF-β1).

Subchondral bone

I-ONE® therapy prevents the sclerosis of the subchondral bone and facilitates the bone oedema reabsorption.

I-ONE® therapy performs a triple action:

1. **ANTI-INFLAMMATORY ACTION ON THE WHOLE ARTICULATION**
2. **ANABOLIC ACTION ON THE CARTILAGE**
3. **TROPHIC ACTION ON THE SUBCONDRAL BONE**

A modern, innovative and reliable technology

» ACTUAL SIZE IMAGE «



»PORTABLE DEVICE«

Unique

A biophysical signal covered by international patents makes I-ONE® therapy unique and **not reproducible.**

Safe

The therapy parameters are preset by IGEA and cannot be modified by the patient, in compliance with the current legislation. To guarantee safety, effectiveness and simplicity of use I-ONE® therapy is **entirely manageable with a single button.**

Compliant

A light, flexible and ergonomic coil guarantees the best possible freedom of movement.

Effective

The effectiveness of the therapy is guaranteed by the homogeneous distribution of the biophysical signal in the area to be treated in the same manner as drug therapy.

Sites treatable with I-ONE® therapy



Early Osteoarthritis

I-ONE® therapy is indicated in patients with grade 0-2 osteoarthritis, according to the Kellgren-Lawrence classification, presenting pain and functional limitation.

I-ONE® therapy

- **Exerts a chondroprotective effect**
- **Controls pain**
- **Improves joint functionality**



Gobbi A et al. JST, 2011

The use of I-ONE® therapy controlled pain, improved quality of life and brought about a full return to the activities of daily living.
To maintain long-term results from the use of I-ONE® therapy it is advisable to repeat the treatment annually.

Bone Oedema / SONK

I-ONE® therapy is indicated in symptomatic patients with acute or chronic bone edema of idiopathic, post-traumatic or degenerative origin.

I-ONE® therapy

- **Enhances the process of oedema reabsorption**
- **Treats pain and improves activity level**
- **Delays arthroplasty surgery**

REDUCTION OF **PAIN** IN
75% OF THE PATIENTS
AT 6 MONTHS FOLLOW-UP



Marcheggiani Muccioli GM et al. Eur J Radiol, 2013

CLINICAL CASE

BEFORE



I-ONE® therapy

AFTER 3 MONTHS



Courtesy dr Marcheggiani Muccioli (Bologna, Italy)

Algodystrophy

I-ONE® therapy is indicated in patients with Type I algodystrophy or CRPS (Complex Regional Pain Syndrome).

I-ONE® therapy

- **Controls the joint inflammatory process**
- **Treats pain**
- **Inhibits osteoclastogenesis**

QUOTED by **SICM GUIDELINES** and by **TUSCANY REGION GUIDELINES.**



I-ONE® therapy **ACTING ON INFLAMMATION**, oedema and pain, TO STOP THE VICIOUS CIRCLE

CLINICAL CASE

BEFORE **I-ONE® therapy** **AFTER**

Borelli PP. Chir Mano, Vol. 54(3) 2017

Patellofemoral Pain Syndrome



I-ONE® therapy is indicated in patients with Patellofemoral Pain Syndrome (PFPS) with pain localised in the anterior part of the knee when walking or doing sporting activities.

I-ONE® therapy

- **Treats pain**
- **Reduces NSAIDs consumption**
- **Allows a rapid return to sporting activity**

RESUMPTION OF SPORTING ACTIVITY



PAIN RESOLUTION



Iammarrone Servodio C et al. Bioelectromagnetics, 2015

IGEA®
CLINICAL BIOPHYSICS

Clinical indications

- EARLY OSTEOARTHRITIS
- JOINT INFLAMMATION
- INTRA ARTICULAR EFFUSION
- BONE OEDEMA / SONK
- PATELLOFEMORAL PAIN SYNDROME
- ALGODYSTROPHY (CRPS)




Daily treatment time: 4 hours. Treatment duration: 30-60 days.
The therapy can be repeated.

References

- Benazzo F et al. Cartilage repair with osteochondral autografts in sheep: effect of biophysical stimulation with pulsed electromagnetic fields. J Orthop Res. 2008 May;26(5):631-42
- Fini M et al. Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs. Biomed Pharmacother. 2008 Dec;62(10):709-15
- Gobbi A et al. L'uso dei campi elettromagnetici pulsati in pazienti sintomatici con lesioni degenerative della cartilagine del ginocchio: un rapporto preliminare. Journal of Sports Traumatology. 2011;Vol. 28, No. 4. Dicembre 2011
- Ongaro A et al. Chondroprotective effects of pulsed electromagnetic fields on human cartilage explants. Bioelectromagnetics. 2011 Oct;32(7):543-51
- Bruscoli R. Necrosi del CFM del ginocchio in un podista master. Trattamento con CEMP. ReaLiMe, Maggio 2012;14:15
- Ongaro A et al. Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts. J Cell Physiol. 2012 Jun;227(6):2461-9
- Marcheggiani Muccioli GM et al. Conservative treatment of spontaneous osteonecrosis of the knee in the early stage: Pulsed electromagnetic fields therapy. Eur J Radiol. 2013 Mar;82(3):530-7
- Gobbi A et al. Symptomatic Early Osteoarthritis of the Knee Treated With Pulsed Electromagnetic Fields: Two-Year Follow-up. Cartilage. 2014 Apr ; 5(2) :76-83
- Ongaro A et al. Pulsed electromagnetic fields stimulate osteogenic differentiation in human bone marrow and adipose tissue derived mesenchymal stem cells. Bioelectromagnetics. 2014 Sep;35(6):426-36
- Veronesi F et al. In vivo effect of two different pulsed electromagnetic field frequencies on osteoarthritis. J Orthop Res. 2014 May;32(5):677-85
- Fini M et al. Razionale d'uso della stimolazione biofisica nell'algodistrofia. Chirurgia della Mano - Vol. 52 (3) 2015
- Veronesi F et al. Experimentally induced cartilage degeneration treated by pulsed electromagnetic field stimulation; an in vitro study on bovine cartilage. BMC Musculoskelet Disord. 2015 Oct 20;16(1):308
- Veronesi F et al. Pulsed electromagnetic fields combined with a collagenous scaffold and bone marrow concentrate enhance osteochondral regeneration: an in vivo study. BMC Musculoskelet Disord. 2015 Sep 2;16:233
- Massari L. La stimolazione biofisica articolare. Giornale Italiano di Ortopedia e Traumatologia. 2016;42(Suppl.1):S73-S78
- Servodio Iammarrone C et al. Is there a role of pulsed electromagnetic fields in management of patellofemoral pain syndrome? Randomized controlled study at one year follow-up. Bioelectromagnetics. 2016 Feb;37(2):81-8
- Massari L et al. Impiego clinico della stimolazione elettrica in ortopedia e traumatologia. Giornale Italiano di Ortopedia e Traumatologia. 2017;43:105-106
- Pagani S et al. Complex Regional Pain Syndrome Type I, a Debilitating and Poorly Understood Syndrome. Possible Role for Pulsed Electromagnetic Fields: A Narrative Review. Pain Physician. 2017 Sep;20(6):E807-E822
- Varani K et al. Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields," Mediators of Inflammation, vol. 2017, Article ID 2740963, 2017. doi:10.1155/2017/2740963

This folder refers to the medical device ref.CBA-03, Series I-ONE.
The device complies with the Medical Device Directive 93/42/EEC and its revised version. The device is marked CE 0051.
The device complies with the standard IEC 60601-1 - for the basic safety and essential performance of Medical electrical equipment.
The device complies with the standard IEC 60601-1-11 for the Medical electrical equipment used in the home healthcare environment.

IGEA/E024/06/18

IGEA®
CLINICAL BIOPHYSICS

Via Parmenide, 10/A | 41012 Carpi (MO) Italy | phone +39 059 699600 | www.igeamedical.com | info@igeamedical.com